Clinical Trial Update: GV1001 Subcutaneous for the Treatment of Moderate to Severe Alzheimer's Disease(AD) [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial of subcutaneous GV1001 for moderate to severe Alzheimer's disease is planned, with recruitment not yet started.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• GV1001

Snippet

Sponsor: Samsung Pharmaceutical Co., Ltd. | Conditions: Moderate to Severe Alzheimer's Disease | Phase 3 | Status: NOT_YET_RECRUITING